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Abstract 
Antibody-drug conjugates (ADCs) are derived from antibodies covalently attached to highly potent 
drugs using a variety of conjugation and linker technologies. This class of therapeutic conceptually 
combines the exquisite specificity of antibodies (i.e. enabling discrimination between healthy and 
diseased tissue) with the cell-killing ability of potent cytotoxic drugs. This powerful and exciting class 
of targeted therapy has shown considerable promise in the treatment of various cancers with two US 
Food and Drug Administration (FDA) approved ADCs currently on the market (i.e. Adcetris™ and 
Kadcyla™) and ca. 40 ADCs currently undergoing clinical evaluation. However, in order for ADCs 
to deliver their full potential, sophisticated site-specific conjugation technologies to connect the drug 
to the antibody are vital. This perspective discusses the strategies currently used for the site-specific 
construction of ADCs and appraises their merits and disadvantages.  
i. Introduction 
Antibodies are macromolecular Y-shaped proteins of ca. 150 kDa and above (see Figure 1), which are 
produced by B-cells in the blood upon activation of the immune system. Antibodies can be generated 
to selectivity target a specific antigen binding partner that is unique to, or over-expressed, on cancer 
cells and have therefore received much attention in cancer treatment in recent years as they greatly 
reduce off target toxicity. These targeted antibodies can be used as therapeutics alone, via antibody-
dependent cell-mediated cytotoxicity, or as vehicles for drug delivery and imaging. 
Antibody-drug conjugates (ADCs) are a type of targeted therapy. They consist of an antibody armed 
with potent cytotoxic drugs using various conjugation and linker technologies. The antibody’s binding 
region allows selective targeting of certain cell types (i.e. allowing for discrimination between healthy 
and diseased tissue) and the potent cytotoxic drug element effects cell-killing independent of 
antibody-dependent cell-mediated cytotoxicity. Hence, ADCs offer the prospect for delivery of a toxic 
payload directly to a target, with minimisation of “off-target” toxicity. This in turn allows for the use 
of particularly toxic drug molecules that are conventionally excluded from use in chemotherapy. 
The concept of delivering a toxic payload to cancer cells using a targeting agent dates back to 1913 
when Paul Ehrlich described a “heptophore” that can deliver a “toxophore” selectively to a tumor.1 
However, it took 45 years for such a species to be constructed in the form of an ADC.
2
 In the 1970’s, 
ADCs were first tested on animals
3, 4
 and less than a decade later the first tests on humans showed 
promising results.
5
 The first ADCs based on chimeric and humanised monoclonal antibodies (mAbs) 
were reported in the 1990s,
6
  and throughout this decade, ever increasing payload potency and 
improved target selection were achieved.
7
 These advances finally led, in 2000, to the first US Food 
and Drug Administration (FDA) approved ADC (Mylotarg, gemtuzumab ozogamicin).
8
 
Despite promising preliminary results, Mylotarg was voluntarily withdrawn from the market in June 
2010 as post-approval clinical trials for patients with acute myeloid leukemia showed that the ADC 
offered no clinical benefit over standard chemotherapy. Nevertheless, this class of targeted therapy 
showed considerable promise in the following years with two further ADCs gaining FDA approval 
(i.e. Adcetris, brentuximab vedotin in 20119, 10 and Kadcyla, trastuzumab emtansine in 201311, 12). It is 
estimated that there are ca. 40 ADCs currently in the clinic and it is predicted that the market for 
ADCs will grow rapidly in coming years.
13
  
Both Kadcyla and Mylotarg were generated by modifying accessible lysine residues on the surface of 
the relevant antibody.
11, 12
 In fact, many ADCs are conjugated through lysine modification. However, 
with ca. 90 accessible lysines, any chemical modification strategy that is non-selective has the 
potential to generate complex mixtures, with up to 10
6
 distinct species statistically possible when 
targeting drug-to-antibody ratios of 2–4. Such heterogeneous mixtures of ADCs may differ in both 
drug loading and conjugation site and this can result in a narrow therapeutic window with major 
pharmacokinetic implications. Although this non-specific conjugation technique has been used in 
FDA-approved ADCs, the use of non-selective approaches is now considered suboptimal in 
developing next generation ADCs.  
In order for ADCs to deliver their full potential, sophisticated conjugation technologies to connect the 
cytotoxic drug to the antibody are needed. In a promising early development, Adcetris was obtained 
by reacting some of the eight free cysteines obtained by reduction of the four interchain disulfides of 
an antibody (see Figure 1). Whilst this approach still generates ca. 15 different species when targeting 
typical average drug-to-antibody ratios of 2–4, it offers a significant improvement over lysine 
modification strategies in terms of reduced heterogeneity.
14
 There is a growing appreciation of the 
importance of developing site-specific methods, with several reports highlighting the advantages for 
generating near homogenous conjugates due to a better defined and improved pharmacokinetic 
profile.
14-16
 This perspective will give an overview of the different methods used for the site-specific 
attachment of cytotoxic agents to antibodies.  
 
ii. Current methods for site-selective attachment of drugs to antibodies  
a. Engineered antibody modification 
With the rapid advances in protein engineering, methods to site-specifically functionalise antibodies 
have become more accessible in recent years. There are three main strategies to generate site-
selectively modified ADCs with re-engineered mAbs (see Figure 2): (i) insertion of cysteine residues 
in the antibody sequence by mutagenesis;
17, 18
 (ii) enzymatic conjugation;
19
 and (iii) insertion of an 
unnatural amino acid with a functional group that can be chemoselectively reacted.
20-22
 
i. Engineered cysteines 
The thiol moiety of the cysteine side chain has the highest nucleophilicity of all proteinogenic amino 
acid functional groups under physiological conditions. This makes it a useful target for the selective 
and site-specific modification of antibodies. Moreover, with the use of site-directed mutagenesis, 
cysteine residues can readily be inserted at a specific position on a protein. 
In 2008, Junutula et al. (Genentech) described a method for the introduction of additional cysteine 
residues on a mAb using site-directed mutagenesis.
23
 This procedure is non-trivial for an antibody as 
the engineered cysteine residues can pair with other free cysteines (e.g. to form protein dimers or to 
scramble disulfides), which could reduce or remove activity.
24, 25
 However, by screening conjugation 
sites on an antibody against the ovarian cancer antigen MUC16, an engineered thio-antibody 
(THIOMAB) containing two new cysteine sites for attachment was generated successfully. 
However, although the engineered cysteines were introduced successfully, they were mostly found as 
mixed disulfides with glutathione. As no reliable method to target reduction of these mixed disulfides 
over native disulfides was achieved, an alternative strategy was needed for engineered thiol 
unmasking. To do this, both the mixed and native interchain disulfides were reduced initially. This 
was followed by mild re-oxidation of the interchain disulfides with a gentle oxidant (e.g. CuSO4) to 
afford an antibody with all of its native disulfide bonds intact, and two reduced engineered cysteines 
available for conjugation. 
Using this strategy, ADCs comprised of monomethyl auristatin E (MMAE), a potent tubulin inhibitor, 
and an anti-MUC16 mAb were generated. They were judged to have an average drug-to-antibody 
ratio of 1.9 with more than 90% homogeneity and were active in vitro and in vivo.
18
 The THIOMAB-
drug conjugates were also shown to be significantly less toxic in rat and cynomolgus monkey models 
when compared with analogous ADCs that were obtained by lysine conjugation with an average drug-
to-antibody ratio of 4. Moreover, as described by Hamblett et al., despite having half the average drug 
load, the THIOMAB-drug conjugates were as efficacious in vivo.
14, 18
 
ii. Enzyme-directed modification 
Another approach to achieving site-selective modification is via enzymes that react with a particular 
amino acid in a specific amino acid sequence. This has been used to site-selectively attach drugs to 
antibodies. 
Transglutaminases 
Transglutaminases (TGs) play an important role in biological processes which depend on the covalent 
crosslinking of proteins,
26
 where they catalyse the formation of amide bonds between the primary 
amine of a lysine and the amide group of a glutamine. However, bacterial TG isolated from 
Streptoverticillium mobaraense has an atypical catalytic site compared to other TGs.
27, 28
 It does not 
catalyse a reaction with any of the naturally occurring glutamine residues in the constant regions of an 
antibody, but will recognise a “glutamine tag” (i.e. LLQG).29 By appraising the merits of 
incorporation of this sequence into 12 surface accessible regions of an anti-M1S1 IgG1, Strop et al. 
(Rinat-Pfizer) found two optimal locations for the “Q-tag”. Two ADCs based on monomethyl 
dolastatin 10 (MMAD, a potent tubulin inhibitor) were then generated. These conjugates were found 
to have good biophysical properties and a drug-to-antibody ratio of ca. 1.9.
16
 Furthermore, when 
compared with an analogous ADC with a higher drug loading (average drug-to-antibody ratio of 3.6) 
based on cysteine alkylation post-native interchain disulfide reduction, the glutamine-tagged ADCs 
showed similar activity in vitro and in vivo and were better tolerated in vivo. This differential in 
toxicity profile suggests that either the selected position of the drug and/or the lower loading offers 
the possibility for improvement of the therapeutic index of ADCs. 
Formylglycine-generating enzymes 
Formylglycine-generating enzymes (FGE) catalyse the selective conversion of a cysteine to an 
aldehyde when in a CXPXR sequence (where X is usually serine, threonine, alanine or glycine). The 
incorporated aldehyde can then be readily functionalised with aminooxy- or hydrazine-functionalised 
molecules.
30
 Using this approach, Drake et al. (Redwood Bioscience) recently produced and 
characterised a series of functionalised antibodies bearing the aldehyde tag at different sites on 
trastuzumab.
31
 They then used hydrozino-iso-Pictet-Spengler (HIPS) chemistry to conjugate a 
cytotoxic maitansine derivative (a potent microtubule-targeted agent) at three different positions. As 
observed with other methods, the site of conjugation had a significant impact on in vivo efficacy and 
pharmacokinetic profile in rats. Unfortunately, this method suffers from the hydration of the aldehyde 
from formyglycine in water to form an unreactive gem-diol, which lowers the yield of the process.
21
  
iii. Unnatural amino acid incorporation  
Recent advances in development of methods for the incorporation of unnatural amino acids into 
proteins have presented opportunities for the site-selective modification of antibodies.
22, 32
 Two 
unnatural amino acids, p-acetylphenylalanine and p-azidophenylalanine, have been particularly useful 
in generating bioconjugates through oxime ligation and classical click chemistry, respectively.  
Axup et al. described the incorporation of p-acetylphenylalanine into several residues in the constant 
region of trastuzumab to construct several modified antibodies ready for site-specific ADC 
synthesis.
22
 Using this unique functional group, MMAD was coupled through a stable oxime-ligation 
process to yield several near-homogenous ADCs with a drug-to-antibody ratio of ca. 2.0. The 
resulting conjugates demonstrated good pharmacokinetic properties, potent in vitro cytotoxic activity 
against HER2+ cancer cells, and complete tumor regression in rodents. When compared with ADCs 
prepared by cysteine alkylation post-native interchain disulfide reduction, site specific unnatural 
amino acids-based ADCs were shown to have increased in vitro cytotoxicity and in vivo efficacy. 
They also had superior in vitro serum stability and an improved toxicology profile in rats.
33, 34
 
Zimmerman et al. (SutroBiopharma) recently observed a similar trend in vitro by incorporating 
p-azidomethyl-phenylalanine into trastuzumab and using strain-promoted azide-alkyne cycloaddition 
click chemistry to conjugate monomethyl auristatin F (a potent tubulin inhibitor).
32
  
Even though these unnatural amino acids methods offer the possibility of generating homogenous 
conjugates by attachment of a drug at virtually any accessible site on a mAb, the potential 
immunogenicity of unnatural amino acids is not yet fully understood and more studies are needed to 
ensure the safety of these engineered ADCs. 
b. Native antibody modification 
Although the aforementioned methods offer the possibility to synthesise near homogeneous ADCs 
they require site-directed mutagenesis and optimisation of cell culture conditions, which can increase 
the overall manufacturing cost of an ADC. The alternative is to develop methods which avoid the 
requirement for re-engineering by direct site-selective manipulation of native mAbs (see Figure 3). 
i. Reduced inter-chain disulfides as targets for site selective modification 
Whilst antibodies typically have approximately 90 accessible lysine residues, reduction of the 4 
accessible interchain disulfides yields only 8 nucleophilic cysteine residues. Hence, conjugation to 
antibodies by reaction with cysteine thiols liberated from reduced interchain disulfides will inherently 
generate a smaller subpopulation of immunoconjugates compared with modification via lysine. 
Moreover, reduction of native interchain disulfide bonds is thought to have a limited effect on 
antibody structure and stability since assembly of light and heavy chains does not depend primarily on 
covalent disulfide linkages, but rather on non-covalent interactions.
14, 35
 
1. Conjugation of cysteines liberated from reduced interchain disulfides 
In 1990, Braslawsky et al. described the use of conjugation to cysteines generated by reduction of the 
native interchain disulfides of a mAb as an ADC construction strategy. Through employing thiol-
bearing doxorubicin as a toxin, a disulfide linker-based ADC was generated. However, whilst the 
resulting ADC was active in vitro, poor potency was observed in vivo.
36
 This limited potency was 
attributed to the instability of the disulfide linker used.  
A decade later, Doronina et al. (Seattle Genetics) used a similar approach of initially reducing the 4 
interchain disulfide bonds of a chimeric anti-CD30 mAb (i.e. cAC10) but conjugating the liberated 
cysteines to MMAE using a maleimide linker. This provided an ADC that was potent and selective for 
CD30-positive hematologic malignancies.
37
 Originally, the 8 sulfhydryl groups generated by 
reduction of the interchain disulfides (see Figure 1) were alkylated using maleimide-MMAE, yielding 
a near homogenous conjugate with a drug-to-antibody ratio of 8. However, further analysis by 
Hamblett et al. and Beckley et al. showed that the high drug loading had a significant impact on 
conjugate phramacokinetics (i.e. poor tolerability, high plasma clearance rate and decreased efficacy 
in vivo) and propensity to aggregate,
14, 38
 and that a lower drug-to-antibody ratio resulted in a larger 
therapeutic window.
14
 In particular, they showed that an ADC with a drug-to-antibody ratio of 4 was 
significantly less toxic to mice than higher loaded conjugates. These observations, along with a 
screening of various reduction/re-oxidation strategies, resulted in a novel site-selectively modified 
antibody, Adcetris, with an average drug-to-antibody ratio of 4 with isomeric homogeneities up to 
75%.
35
 However, one of the main drawbacks of this strategy comes from the use of maleimide 
chemistry in that the resulting bioconjugate is known to undergo retro-addition reactions with blood 
thiols, resulting in the transfer of drug to thiol-bearing proteins and thus leading to off-site toxicity.
39
 
Recently, however, several strategies to overcome this issue and to obtain thiol-stable bioconjugates 
have been developed.
40
 
2. Re-bridging of cysteines liberated from reduced interchain disulfides 
To target a drug-to-antibody ratios of 4 and increase the overall homogeneity of their conjugates, 
Badescu et al. (PolyTherics) explored the possibility that reduction of the interchain disulfide bridges 
could be followed by functional re-bridging of the disulfide (see Figure 3). This would allow insertion 
of a single cytotoxic payload per disulfide and retain a covalent link between the protein chains. Their 
method is based on bis-cysteine-selective sulfone reagents that allow for an addition-elimination-
addition sequence onto the reduced disulfide bonds of either Fabs or mAbs. Using MMAE as the toxic 
payload on both trastuzumab and its Fab, they successfully demonstrated increased efficacy over drug 
alone whilst retaining binding and antigen-selective cytotoxicity in vitro, along with efficacy in vivo.
41
 
Other groups (i.e. Chudasama, Baker and Caddick) have also developed reagents that allow for the 
efficient functional re-bridging of interchain disulfides (i.e. dibromopyridazinediones and 
dithiomaleimides).
42, 43 
Using these reagents on both trastuzumab and its Fab, Maruani et al. and 
Nunes et al. have successfully generated near homogeneous ADCs with in vitro efficacy.
42, 43
  
ii. Glycan targeting for synthesis of antibody-drug conjugates 
All antibodies are glycosylated at conserved positions in their constant regions; they possess an 
N-glycosylation site at the conserved Asn-297 residue of the Fc region (see Figure 1). Thus, this 
serves as a potentially interesting (and generic) site for antibody modification. 
In this context, the use of hydrazone chemistry to attach a cytotoxic agent onto the glycans of an 
unmodified native antibody has found considerable utility.
44, 45
 Sodium periodate at high concentration 
has been used to oxidise carbohydrate residues in the native glycans to provide aldehydes which are 
used for ligation to afford relatively homogenous ADCs.
45
 The main drawback of this approach arises 
from the harsh oxidation conditions required to generate the aldehydes, which can result in oxidation 
of methionine residues located close to FcRn binding site. This over-oxidation is known to affect 
FcRn binding and to generally reduce serum half-life.
46
 To alleviate this issue, milder enzymatic 
methods have been developed, which are discussed below. 
Neuraminidases 
Through sequentially using neuraminidases to cleave the glycosidic linkages of neuraminic acids and 
Gal oxidase to oxidise the galactose residues of an anti-CEA mAb, Stan et al. site-selectively attached 
doxorubicin via reductive amination on the generated aldehydes.
15
 The resulting ADC had a drug-to-
antibody ratio of 3.7 and was four times more toxic in vitro than its counterpart generated by lysine 
conjugation with a drug-to-antibody ratio of 7.8. This demonstrates once again the importance of, and 
therapeutic opportunities for, site specificity in ADC construction. 
Glycosyltransferases 
Recently, Zhou et al. (Sanofi-Genzyme) described another approach using post-translational 
modification of trastuzumab to introduce sialic acid moieties onto the native glycans on Asn-297.
47
 To 
achieve site-specific modification, a mixture of galactosyltransferase and sialyltransferase was used to 
transfer galactose and sialic acid residues onto the native glycans. These sialic acid residues were then 
oxidised under mild condition to yield aldehyde-functionalised trastuzumab. Even though these 
conditions led to partial oxidation of the methionines proximal to the FcRn binding site, which 
compromised FcRn binding by ca. 25%, it had a negligible effect on serum half-life.
47
 The 
enzymatically modified mAb was then conjugated by oxime ligation with aminooxy drug linkers to 
generate site-selectively modified ADCs. Using MMAE and MMAD, an average drug-to-antibody 
ratio of 1.6 was obtained and these glyco-conjugated ADCs exhibited antigen-dependent activity in 
vitro and were efficacious in vivo. 
A similar strategy that avoids the oxidation step by utilising azido-modified sialic acid and strain-
promoted azide-alkyne cycloaddition chemistry with a suitable doxorubicin derivative has recently 
been applied to an anti-CD22 antibody. This resulted in a near homogenous ADC which has been 
shown to selectively target and kill lymphoma cells in vitro.
48
 
The main limitation of these glycan-based modifications stems from the complex and heterogeneous 
population of glycans in mAbs, as well as their reliance on the presence of galactose on an IgG1. 
These characteristics of antibodies may reduce the homogeneity of the final ADC construct and/or 
mean that additional steps are required to homogenise the glycan population.
49
 
iii. Conclusion and future outlook 
In conclusion, a variety of methods have been developed for the site-selective modification of 
monoclonal antibodies to produce antibody-drug conjugates, each with their own advantages and 
limitations (Table 1). Although the use of engineered mAbs for ADC construction offers controlled 
homogeneity, this is offset by their construction and modification often being technically challenging. 
Modification of native mAbs, on the other hand, involves simple reaction protocols but with the 
caveat of difficulties in achieving homogeneous modification. Thus there is no leading technology at 
present and although recent methods for the construction of ADCs have gone some way to addressing 
the challenging issues of making homogeneous antibody-drug conjugates, significant hurdles still 
remain. Despite there being a link between a number of parameters that one needs to consider when 
constructing an ADC (e.g. location of cytotoxic agent, drug-to-antibody ratio, homogeneity) and the 
efficacy and pharmacokinetic profile of the ADC (e.g. required dosage, biodistribution, clearance rate, 
toxicity, accumulation at tumour), the detailed understanding of the interdependencies of these links 
and combinations of parameters will need a good deal more work before they are fully understood. 
Even though there appears to be general recognition that site-specific ADCs with increased 
homogeneity are likely to have superior therapeutic properties, there is not as yet a single technology 
that can be generally applied for their preparation. Instead, each ADC is being constructed in a tailor-
made fashion for the specific antibody and drug combination in question. At this time, it is unclear 
what site-specific strategies will be ideal for what drug types or drug-to-antibody ratios, or even 
which ones will meet low manufacturing cost, safety and tolerability requirements. However, with a 
better understanding of the influence and consequences of each site-specific modification strategy in 
the coming years, the next generation of antibody-based targeted therapy will be based on a more 
rational design of bioconjugates to connect the “A” and the “D”. Perhaps a leading single technology 
will emerge, or particular technologies will be more suited to certain drug types, drug loadings or 
specific antibodies, however, what is for certain is that ADCs have an important and longstanding role 
to play in the future of targeted therapeutics.  
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Legends 
Figure 1: General structure of an IgG1 antibody highlighting key components. Fab fragments 
comprise the antigen-binding region and consist of the whole light chain (VL and CL) and of part of 
the heavy chain (VH and CH1). Fab fragments have a molecular weight of ca. 50 kDa. The Fc 
fragment carries some of the biological properties of the IgG1, in particular its ability to be recognised 
by effectors of immunity. It consists of identical CH2 and CH3 fragments, derived from the heavy 
chains’ constant domains of the antibody. Fc fragments do not recognise the corresponding antigen, 
they bind to various cell receptors and complement proteins and have a molecular weight of ca. 50 
kDa. All antibodies are glycosylated at conserved positions in their constant regions (C); they possess 
an N-glycosylation site at the conserved Asn-297 residue of the Fc region. 
Figure 2: General scheme highlighting typical methods for the construction of ADCs based on the 
engineering of antibodies. The engineering methods highlighted consist of: THIOMAB cysteine 
engineering followed be alkylation; unnatural amino acid incorporation followed by click ligation; 
Glutamine-tag (Q-tag) insertion followed by transglutaminase functionalisation; and use of 
formylglycine-generating enzyme to generate an aldehyde followed by hydrozino-iso-Pictet-Spengler 
functionalisation.  
Figure 3: General scheme highlighting typical methods for the construction of ADCs based on “off-
the-shelf” antibodies. The methods highlighted consist of: native glycan targeting to yield aldehyde-
modified mAb by oxidation followed by reductive amination or O-substituted oxime 
functionalisation; and disulfide reduction followed by either cysteine alkylation using maleimide or 
functional disulfide re-bridging. 
Table 1: A summary of the advantages and limitations of the site-selective methods described. 
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screening 
Incorporation of non-orthogonal 
group leads to issues of ADC 
production 
2 
Enzyme directed 
Ease of incorporation, 
homogeneity  
Efficiency is site and antibody-
dependent 
2 
Unnatural Amino 
Acid (UAA) 
Chemoselectivity, 
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potential immunogenicity issues 
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Conjugation of 
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disulfide reduction 
Ease of preparation, 
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disulfides 
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protein chains 
Potential disulfide scrambling 4 
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modification 
Ease of preparation, 
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selectivity  
Heterogeneous glycan 
population, reduced FcRn 
binding due to undesired 
oxidation 
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